| 李开春,王雅杰.激素受体阳性晚期乳腺癌内分泌治疗选择[J].肿瘤学杂志,2020,26(1):7-12. |
| 激素受体阳性晚期乳腺癌内分泌治疗选择 |
| Choice of Endocrine Therapy for Advanced Breast Cancer with Hormone Receptor Positive |
| 投稿时间：2019-09-20 |
| DOI：10.11735/j.issn.1671-170X.2020.01.B002 |
|
 |
| 中文关键词: 乳腺肿瘤 肿瘤转移 激素类 受体 药物疗法 |
| 英文关键词:breast neoplasms neoplasm metastasis hormones receptors drug therapy |
| 基金项目: |
|
| 摘要点击次数: 1969 |
| 全文下载次数: 439 |
| 中文摘要: |
| 摘 要：激素受体阳性乳腺癌占所有乳腺癌的70%。内分泌治疗是这个亚型乳腺癌的主要治疗手段，最常见药物有他莫昔芬和芳香酶抑制剂如阿拉曲唑、来曲唑和依西美坦。全文重点总结新型内分泌治疗药物，如雌激素受体降解剂（Fulvestrant），以及新的靶向药物如mTOR抑制剂（Everolimus）、CDK4/6抑制剂（Palbociclib、Ribociclib和Abemaciclib）和PI3K抑制剂（Alpelisib、Buparlisib和Pictilisib）等。新的靶向药物联合内分泌治疗已经改变了临床实践，延长激素受体阳性晚期乳腺癌患者的生存期。 |
| 英文摘要: |
| Abstract：Hormone receptor-positive breast cancer accounts for 70% of all breast cancer. Endocrine therapy is the main treatment for this type of breast cancer，and the most common drugs are tamoxifen and aromatase inhibitors such as alatrozole，letrozole and exemestane. This review focuses on new endocrine therapy drugs，such as estrogen receptor degradants(Fulvestrant)，and new targeted drugs such as mTOR inhibitors(Everolimus)，CDK4/6 inhibitors(Palbociclib，Ribociclib and Abemaciclib) and PI3K inhibitors(Alpelisib，Buparlisib and Pictilisib). New targeted drugs combined with endocrine therapy have changed clinical practice and significantly prolonged the survival of hormone receptor-positive advanced breast cancer patients. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |